| abstract |
Platelet activating factor receptor antagonists of various structures are imparted with 5-1-hypoxygenase activity by adding an entity such as hydroxamate, hydroxyurea, oxacane, thioalkane, quinolimethox, or amidohydroxyurea to the PAF receptor antagonist at a position on the PAF antagonist molecule that demonstrates 'volumetric tolerance', that is, the ability to adjust functionality without significant loss of PAF activity. |